AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of AMG 531 in the treatment of
thrombocytopenia in subjects with ITP as measured by the platelet response. This study will
also evaluate changes in Patient Reported Outcomes and Health Resource Utilization due to
treatment with AMG 531.